Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade

Figure 1

Progression-free survival (PFS) stratified by median differences in neutrophil-to-lymphocyte ratio (NLR) between baseline and after 2 doses of treatment with an anti-PD-1/PD-L1 inhibitor, showing longer PFS in patients with a reduction of NLR compared to the median baseline NLR.